Novartis's everolimus gains first European approval for rare benign brain tumour
This article was originally published in Scrip
Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novartis' everolimus its first European approval for the treatment of a benign brain tumour associated with tuberous sclerosis (TS), a rare genetic disease. The approval is for the use of everolimus in patients aged three years and older with subependymal giant cell astrocytoma (SEGA) associated with TS, for whom surgery is not a suitable option. It will be sold under the trade name Votubia.